ID

43531

Descripción

PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00605397

Link

https://clinicaltrials.gov/show/NCT00605397

Palabras clave

  1. 8/6/17 8/6/17 -
  2. 20/9/21 20/9/21 -
Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT00605397

Eligibility Breast Cancer NCT00605397

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
registered patient at mskcc
Descripción

ID.1

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513120
age ≥18 years
Descripción

ID.2

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patients with her2+ metastatic breast cancer (either 3+ by immunohistochemistry or with evidence of gene amplification (>2.0) by fluorescence in situ hybridization (fish))
Descripción

ID.3

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1960398
UMLS CUI [1,2]
C0027627
measurable or evaluable disease
Descripción

ID.4

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0449385
currently taking or about to commence treatment with trastuzumab at a dosing schedule of 2 mg/kg weekly or 6 mg/kg every three weeks, as per standard of care
Descripción

ID.5

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0728747
karnofsky performance score ≥ 60
Descripción

ID.6

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206065
signed informed consent
Descripción

ID.7

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous grade 3 or higher allergic reaction to trastuzumab that resulted in discontinuation of trastuzumab therapy
Descripción

ID.8

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0728747
claustrophobia/pain leading to inability to lie still for the duration of the scanning procedure.
Descripción

ID.9

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0008909
UMLS CUI [1,2]
C0024485
pregnancy test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
Descripción

ID.10

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032976
inability to provide written informed consent.
Descripción

ID.11

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
patients with liver metastases as the only site of distant disease
Descripción

ID.12

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0494165
patients with known sensitivity or contraindication to herceptin.
Descripción

ID.13

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0338204

Similar models

Eligibility Breast Cancer NCT00605397

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
registered patient at mskcc
boolean
C1513120 (UMLS CUI [1])
ID.2
Item
age ≥18 years
boolean
C0001779 (UMLS CUI [1])
ID.3
Item
patients with her2+ metastatic breast cancer (either 3+ by immunohistochemistry or with evidence of gene amplification (>2.0) by fluorescence in situ hybridization (fish))
boolean
C1960398 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.4
Item
measurable or evaluable disease
boolean
C0449385 (UMLS CUI [1])
ID.5
Item
currently taking or about to commence treatment with trastuzumab at a dosing schedule of 2 mg/kg weekly or 6 mg/kg every three weeks, as per standard of care
boolean
C0013216 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
ID.6
Item
karnofsky performance score ≥ 60
boolean
C0206065 (UMLS CUI [1])
ID.7
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.8
Item
previous grade 3 or higher allergic reaction to trastuzumab that resulted in discontinuation of trastuzumab therapy
boolean
C0020517 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
ID.9
Item
claustrophobia/pain leading to inability to lie still for the duration of the scanning procedure.
boolean
C0008909 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
ID.10
Item
pregnancy test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
boolean
C0032976 (UMLS CUI [1])
ID.11
Item
inability to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
ID.12
Item
patients with liver metastases as the only site of distant disease
boolean
C0494165 (UMLS CUI [1])
ID.13
Item
patients with known sensitivity or contraindication to herceptin.
boolean
C0020517 (UMLS CUI [1,1])
C0338204 (UMLS CUI [1,2])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial